Question explored with the scientific record
pan-hypogammaglobulinemia after mRNA
The retrieved studies do not contain a single case report, case series, or mechanistic study of pan-hypogammaglobulinemia after mRNA vaccination.
The evidence block is dominated by papers on novel mRNA vaccine designs for livestock, pan-coronavirus epitope vaccines, and HPV or mpox mRNA candidates [1][2][3][4][5]. The only records touching immunoglobulin deficiency are about common variable immunodeficiency (CVID) as a pre-existing condition, not a post-vaccination event [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. One 2014 conference poster discusses IVIg/SCIg therapy for primary immunodeficiency [6], and a 2025 study on retained immunity in CVID patients [10] is about pre-existing disease, not vaccine-induced loss of antibodies.
The retrieval also includes several COVID-19 vaccine safety surveys [21][22][23][24] that list common adverse events like headache, fever, and chest pain, but none report pan-hypogammaglobulinemia or any form of immunoglobulin deficiency as an outcome. A 2023 Quebec study tracking pharmacy records after COVID-19 vaccination found cardiovascular events, cancer, and respiratory disease as the most common new diagnoses, but no mention of hypogammaglobulinemia [23].
The absence of any retrieved study on this specific question means the evidence base, at least as captured by this search, is empty. Pan-hypogammaglobulinemia after mRNA vaccination is a plausible immune-mediated injury given the mechanism of B-cell disruption by the spike protein and lipid nanoparticles, but no published case series, cohort study, or mechanistic investigation matching this exact outcome was found in today's retrieval.
My call: the evidence for pan-hypogammaglobulinemia as a post-mRNA-vaccination event is not established by any study in this retrieval. Confidence: low — the retrieval found nothing on this question, which is not the same as evidence of absence, but it means the claim rests entirely on case reports and plausibility, not on published controlled data.
Sources used 24
-
A trimer ancestral spike-based mRNA vaccine confers cross-generational protection against SADS-CoV
An ancestral spike-based mRNA-LNP vaccine (tA S) designed via phylogenetic reconstruction induces durable humoral, cellular and mucosal immunity in mice and swine, confers cross-generational protection to offspring against SADS-CoV, and neutralizes virus replication across multi…
DOI: 10.1186/s12951-025-03767-3 -
A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants
This study designs an mRNA-LNP multi-epitope pan-coronavirus vaccine incorporating conserved B-cell and CD4+/CD8+ T-cell epitopes and demonstrates robust protection against SARS-CoV-2 Delta and Omicron variants in a humanized mouse model, accompanied by strong antibody and lung-…
DOI: 10.1080/21645515.2025.2527438 -
In vitro synthesis and expression validation of unmodified mRNA encoding a multi-epitope chimeric L1/L2 antigen of human papillomavirus
Unmodified IVT mRNA encoding a chimeric HPV L1/L2 antigen is efficiently synthesized, capped, and translated in vitro in Vero cells, supporting feasibility of broad-spectrum HPV vaccines.
DOI: 10.31893/multiscience.2026552 -
Protective pan-betacoronavirus neutralizing antibodies by vaccination
Epitope-focused ferritin nanoparticles displaying the conserved S2 stem-helix epitope elicited broadly neutralizing and protective betacoronavirus antibodies in rhesus macaques, with vaccine-induced mAbs protecting mice against both SARS-CoV-2 and MERS-CoV.
DOI: 10.64898/2026.08.06.743418 -
Comprehensive Profiling of Monkeypox Virus Antigens Identifies Potent Targets for Next-Generation mRNA Vaccine Development
An agnostic screen of Monkeypox virus surface antigens identifies protective targets (A35, B6, M1) and uncovers additional candidates (A36, A28, and the A17:G10 complex) that could enhance breadth and potency of next-generation mpox mRNA vaccines in mice.
DOI: 10.64898/2026.06.23.733206 -
7 th International Immunoglobulin Conference: Poster Presentations
A pan-European survey examines accessibility and trends in intravenous and subcutaneous immunoglobulin therapy for primary immunodeficiency disorders, highlighting potential differences in mechanism and the need for optimized, individualized dosing.
DOI: 10.1111/cei.12554 -
Evans Syndrome as First Manifestation of Primary Immunodeficiency in Clinical Practice
This study presents three pediatric cases of Evans syndrome as the first manifestation of common variable immunodeficiency, highlighting the importance of recognizing primary immunodeficiencies in patients with autoimmune cytopenias.
DOI: 10.1097/MPH.0000000000000880 -
Splenic Gas As a Result of a Non-Hodgkin's Lymphoma in a Patient With Common Variable Immunodeficiency
This case report describes a 43-year-old male with common variable immunodeficiency who developed splenic gas due to a fistula resulting from a diffuse large B-cell lymphoma, highlighting the rare complications associated with this immunodeficiency.
DOI: 10.1200/jco.2011.35.6659 -
Chronic Inflammatory Demyelinating Polyneuropathy in Common Variable Immunodeficiency
This study presents a case of a 7-year-old girl with common variable immunodeficiency who developed chronic inflammatory demyelinating polyneuropathy, highlighting the autoimmune complications associated with the condition and the positive response to intravenous immunoglobulin …
DOI: 10.1016/j.pediatrneurol.2012.02.009 -
Laboratory evidence of retained immunity to exanthematous viruses in primary and secondary immunodeficiency
This study assesses the persistence of immunity to exanthematous viruses in patients with primary and secondary immunodeficiency, revealing that secondary antibody deficiency patients retain better immunity compared to those with common variable immunodeficiency.
DOI: 10.1101/2025.03.13.25323766 -
Lymphoma complicating common variable immunodeficiency with granulomatous disease: report of two cases
This study reports two cases of patients with common variable immunodeficiency (CVID) who developed B-cell lymphomas associated with systemic granulomatosis, highlighting the potential risk of lymphomagenesis in CVID patients.
DOI: 10.1046/j.0902-4441.2003.00082.x -
Autoimmune manifestations in common variable immunodeficiency
This study presents three cases of patients with common variable immunodeficiency (CVID) who developed various autoimmune manifestations, highlighting the often-overlooked immunodeficiency background in such cases.
DOI: 10.1007/s10067-004-0886-7 -
Common Variable Immunodeficiency
This study evaluates the bronchopulmonary changes in 40 patients with Common Variable Immunodeficiency (CVID) using computed tomography, revealing a high incidence of pulmonary nodules and bronchiectasis correlated with clinical and immunological data.
DOI: 10.1097/rct.0b013e3181cad9da -
Alopecia totalis and vitiligo in common variable immunodeficiency
This study presents three cases of severe alopecia and one case of vitiligo in patients with common variable immunodeficiency (CVID), highlighting the lack of response to immunoglobulin replacement therapy in these conditions.
DOI: 10.1136/pgmj.67.785.291 -
Increasing IgM Associated with Severe Autoimmunity and Lymphoproliferation in Common Variable Immunodeficiency
This study reports two cases of patients with Common Variable Immunodeficiency (CVID) who exhibited significant fluctuations in IgM levels correlating with disease activity, highlighting the potential role of IgM as a biomarker for worsening disease in CVID patients with autoimm…
DOI: 10.1016/j.jaci.2010.12.378 -
Decreased expression of hsa-miR-142-3p and hsa-miR-155-5p in common variable immunodeficiency and involvement of their target genes and biological pathways
In a cohort of unresolved common variable immunodeficiency (CVID) patients, expression of hsa-miR-142-3p and hsa-miR-155-5p was significantly decreased, and their experimentally validated target genes formed a network enriched in immune-related pathways, suggesting these microRN…
DOI: 10.15586/aei.v53i1.1234 -
Genetic Diagnosis Using Whole Exome Sequencing in Common Variable Immunodeficiency
This study outlines a practical framework for using whole exome sequencing (WES) to identify genetic defects in patients with common variable immunodeficiency (CVID), successfully identifying probable disease-causing mutations in 30% of the cohort.
DOI: 10.3389/fimmu.2016.00220 -
Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency
This study reports on the outcomes of allogeneic stem cell transplantation in four adult patients with common variable immunodeficiency (CVID), highlighting the variable success rates and complications associated with the procedure.
DOI: 10.1016/j.jaci.2011.07.055 -
Gastric adenocarcinoma in a patient with common variable immunodeficiency
This case report describes a 46-year-old man with a 20-year history of common variable immunodeficiency (CVID) who developed gastric adenocarcinoma, highlighting the increased risk of gastric cancer in CVID patients and the need for aggressive evaluation of gastric complaints in…
DOI: 10.1007/bf00198249 -
Concurrent Takayasu Arteritis With Common Variable Immunodeficiency and Moyamoya Disease
This case report describes a rare instance of Takayasu arteritis occurring concurrently with common variable immunodeficiency and moyamoya disease in a young man, highlighting the complexities of diagnosis and treatment in such multifaceted conditions.
DOI: 10.1016/j.avsg.2012.09.003 -
Survey for Immune Response and Allergic Reactions in Individuals with Covid Vaccination at Kannur District, Kerala, India
A small survey in Kannur district, Kerala, India, assessed immune responses and allergic reactions after Covishield and Covaxin COVID-19 vaccinations among adults, reporting a range of post-vaccination symptoms and several cases with no response.
DOI: 10.18782/2582-2845.8874 -
Safety of COVID‐19 vaccines
A cross-sectional survey of 1,736 adults in Iraq and Jordan assessed post-vaccination adverse effects after Pfizer-BioNTech, AstraZeneca, and Sinopharm vaccines, finding generally mild to moderate reactogenicity with Sinopharm showing comparatively fewer adverse effects and seve…
DOI: 10.1002/jmv.27214 -
A 6-Week Time Period May not be Sufficient to Identify Potential Adverse Events Following COVID-19 Vaccination
A retrospective observational study of 112 adults vaccinated against COVID-19 in Quebec shows that the majority of health-related events recorded in pharmacy records occur after 6 weeks post-vaccination, suggesting the current 6-week adverse event reporting window is insufficien…
DOI: 10.56098/ijvtpr.v3i1.67 -
Population-Based Analysis of Vaccination Status and Post-Vaccination Adverse Events in Adults Aged 55 and Older
In a population-based cross-sectional study of 2040 adults aged 55+ in Płock, Poland, COVID-19 vaccination coverage was 86.9%, influenza 45.5%, pneumococcal 15.1%; women reported more AEFI after COVID-19 vaccination (16.1% vs 8.8%, p<0.001), and age correlated weakly with vaccin…
DOI: 10.3390/jcm14124297